We are reproducing an excellent article published this week by KeyFacts Energy.
Genedrive Highlights NIHR Case Study Showing Potential £5m Annual NHS Savings
Genedrive plc (AIM: GDR) has highlighted a new case study published by the National Institute for Health and Care Research examining the development, clinical validation and adoption of its Genedrive
UK Flights Delayed After New NATS Air Traffic Control Technical Issue
Flights across parts of the UK have been delayed after a technical issue at National Air Traffic Services’ Prestwick centre forced restrictions on airspace covering northern and central England, Scotland
Genedrive Expands European Adoption with Erasmus MC Implementation
Genedrive PLC (AIM: GDR) has announced that its Genedrive® MT-RNR1 ID Kit has been implemented at Erasmus MC University Medical Center in Rotterdam, expanding the international adoption of its rapid
Breaking: BP Puts North Sea Business Up for Sale
BP has announced plans to sell its North Sea oil and gas business, bringing to an end more than six decades as an operator in one of the UK’s most
Oil Prices Heading Towards US$100 Mark For The First Time Since May
Oil prices jumped on Thursday as the fallout from the US-Iran conflict appeared to spread to the Red Sea.
Oil Surges Above US$95 as US-Iran Hostilities Continue
Oil prices climbed more than 4% on Wednesday as renewed fighting between the US and Iran raised fresh concerns over global energy supplies.
European gas prices hit a four-month high
European gas prices hit a four-month high on Monday as escalating tensions between the US and Iran fuelled fears of a supply crunch this winter.
Burnham Expected to Signal North Sea Drilling Push as Energy Policy Shifts
Andy Burnham is expected to signal support for more North Sea oil and gas drilling after becoming prime minister, in what could mark an early shift in tone on UK
Genedrive Expects FY26 Income to Rise 40% as NHS Adoption Expands
genedrive plc (AIM: GDR) expects to report total income of £1.4 million for the year ended 30 June 2026, up from around £1.0 million in FY25 and in line with
Genedrive technology showcased in Parliament
Genedrive plc (AIM: GDR) has highlighted comments from UK Health Minister Preet Kaur Gill MP, who cited rapid pharmacogenetic testing for antibiotic-induced hearing loss as a practical example of personalised
genedrive partners with Thermo Fisher on NHS testing
genedrive plc (AIM: GDR) has entered into a product development collaboration with Thermo Fisher Scientific to develop a high-throughput CYP2C19 pharmacogenetic test for deployment on Thermo Fisher’s QuantStudio™ 5 Dx